Bibliographic Details
| Title: |
Treatment Effects of Therapeutic-Dose Heparin in Patients Hospitalized for COVID-19. |
| Authors: |
Davidson, Bruce L.1 (AUTHOR) brucedavidson@pobox.com, Levi, Marcel M.2,3 (AUTHOR) |
| Source: |
JAMA: Journal of the American Medical Association. 8/1/2023, Vol. 330 Issue 5, p471-472. 2p. |
| Subject Terms: |
*COVID-19, *HEPARIN |
| Abstract: |
Comment & Response B To the Editor b A recent study[1] of treatment effects of therapeutic-dose heparin in patients hospitalized for COVID-19 analyzed patients on the ward (treatment-dose heparin was efficacious) separately from critically ill patients (treatment-dose heparin was not efficacious). The authors described this trial design as "fortuitous."[1] However, we are concerned that the no-difference result in critically ill patients may have occurred because subcutaneous depot dosing of low-molecular-weight heparin (LMWH) has poor systemic exposure in critically ill patients, particularly in those receiving vasopressors. [Extracted from the article] |
|
Copyright of JAMA: Journal of the American Medical Association is the property of American Medical Association and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Academic Search Complete |
